Evidence map›Paper›PMID 42457964›Full record

ArticleNature2026

GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma.

Qi Zhang, Qihan Fu, Yinan Shen, Wanyue Cao, Gaowei Jin, Yize Zhang, Jiangchao Wu, Cao Chen, Hongkan Wang, Xingyuan Xu and 25 more

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Qi Zhang *Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.ORCID http://orcid.org/0000-0002-6096-0690
Qihan Fu *MOE Joint International Research Laboratory of Pancreatic Diseases, Hangzhou, China.
Yinan Shen *Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Wanyue Cao *Department of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Gaowei JinDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yize ZhangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Jiangchao WuDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Cao ChenDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Hongkan WangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xingyuan XuDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Ke SunZhejiang University Cancer Centre, Hangzhou, China.
Xing XueDepartment of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Attilio BondanzaOncology R&D, AstraZeneca, Cambridge, UK.
Daisy CaoQuality, Shanghai AbelZeta, Ltd., Shanghai, China.
Nina ChuOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Nick DurhamOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Mark CobboldOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Benedetto FarsaciGlobal Patient Safety, AstraZeneca, Gaithersburg, MD, USA.
Maria Letizia Giardino TorchiaOncology R&D, AstraZeneca, Cambridge, UK.
Yixin HaoClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Yi HongTech & Manufacturing, Shanghai AbelZeta, Ltd., Shanghai, China.
Jiaqi HuangTranslational Medicine, AbelZeta Pharma, Inc., Gaithersburg, MD, USA.
Michael HumphriesClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Qijie JianClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Gordon MoodyOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
John StoneOncology R&D, AstraZeneca, Cambridge, UK.
Lingyan SunClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Eric TuOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Fei WangTech & Manufacturing, Shanghai AbelZeta, Ltd., Shanghai, China.
Fuzhe WangClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Ye YangOncology R&D, AstraZeneca, Gaithersburg, MD, USA.
Yihong YaoImmuno-Oncology R&D, AbelZeta Pharma, Inc., Gaithersburg, MD, USA.
Andy ZouClinical Development, Shanghai AbelZeta, Ltd., Shanghai, China.
Xueli BaiDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Tingbo LiangDepartment of Hepatobiliary and Pancreatic Surgery, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. liangtingbo@zju.edu.cn.ORCID http://orcid.org/0000-0003-0143-3353

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glypican-3 (GPC3) is highly expressed in hepatocellular carcinoma (HCC), making it an attractive target for chimeric antigen receptor (CAR) T cell therapy; however, this approach has previously shown limited clinical efficacy, potentially owing to high levels of transforming growth factor-β (TGFβ) in the tumour microenvironment

Indexed as

Carcinoma, HepatocellularGlypicansImmunotherapy, AdoptiveLiver NeoplasmsReceptors, Chimeric AntigenReceptor, Transforming Growth Factor-beta Type IIT-LymphocytesAdultAgedFemaleHumansMaleMiddle AgedGlypicansGPC3 protein, humanReceptors, Chimeric AntigenReceptor, Transforming Growth Factor-beta Type IITGFBR2 protein, human

Identifiers

PMID42457964

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.